Roger Finch.pdf

More documents

Recommendations

Info

Decline in the licensing of new antibioticsterial AgentsTotal # New Antibac181614121086420*R 2 = 0.99*R 2 =0990.991983-87 1988-92 1993-97 1998-2002 2003-07 2008-present*p = 0.007 by linear regressionNew antibacterial agent≡ new molecular entity (NME) with antimicrobial properties,administered for systemic infection; topical agents and immunomodulators excludedIDSA 2003 – updated March 2011
The Future- pipeline antibacterials (phase III)Drug Class CommentsTelavancin Glycopeptide cSSTI, HAPOritavancin Glycopeptide cSSTINOTE – no newDalbavancin Glycopeptide cSSTI, catheter associatedbacteraemiaagents for MDRIclaprim Antifolate AbandonedGram-negativesCeftobiprole Cephalosporin On holdCeftaroline Cephalosporin Approved by FDAFaropenem Penem Rejected by FDAFidaxomicin Macrocyclic RNA inhibitor Trials completed for CDILactoferrin Peptide Childhood diarrhoeaReport prepared for ARHAI (HPA-AMRL) 2010
Page 1: BSAC: Celebrating 40 years of achie
Page 6 and 7: Development of new classesof antiba
Page 8 and 9: Streptococcus pneumoniae infections
Page 10 and 11: What pathogens/diseasesrequire new
Page 12 and 13: Strategic control of antibioticresi
Page 14 and 15: Key technology needs tosupport thes
Page 16 and 17: The EducationalChallengeUK NHS Staf
Page 18 and 19: Antimicrobial Stewardship Programme
Page 20 and 21: The advantages of better andfaster
Page 22 and 23: POC/Rapid diagnostics and drugDisad
Page 24 and 25: The Way Forward Pharma & biotech -

Roger Finch.pdf

Create successful ePaper yourself

Delete template?

Save as template?